

KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



14th August, 2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

Sub: - Outcome of Board Meeting
- Submission of Un-audited Financial Results for the Quarter ended on 30th June, 2021

Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 30th June, 2021.

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 30th June, 2021 along with Limited Review Report thereon.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,
For KAMRON LABORATORIES LIMITED

Kamlesh J. Laskari
KAMLESH J. LASKARI
MANAGING DIRECTOR
(DIN: 00461198)



Encl: As above.

KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



KAMRON

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2021

(Rs. In lakh)

Particulars		Quarter ended			Previous Year ended 31-03-2021
		30-06-2021	31-03-2021	30-06-2020	
		(Unaudited)	(Audited)	(Unaudited)	
(Refer Notes Below)					(Audited)
1	Revenue from operations	63.14	207.21	136.21	632.52
2	Other income	0.00	0.21	0.00	0.33
3	Total Income (1+2)	63.14	207.42	136.21	633.15
4	Expenses				
	a. Cost of Materials consumed	-	-	-	-
	b. Purchases of stock-in-trade	32.14	52.02	58.20	233.26
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	13.08	51.42	13.62	69.96
	d. Employee benefits expense	6.25	56.88	28.56	171.43
	e. Finance costs	0.44	2.37	0.24	3.27
	f. Depreciation & amortisation expense	25.58	16.29	28.66	102.34
	g. Other expenses	13.72	56.45	32.97	181.22
	Total Expenses	91.21	235.43	162.25	761.48
5	Profit / (Loss) before exceptional items and tax (3-4)	(28.07)	(28.01)	(26.04)	(128.33)
6	Exceptional items	-	-	-	-
7	Profit / (Loss) before tax (5-6)	(28.07)	(28.01)	(26.04)	(128.33)
8	Tax expense:				
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
9	Profit (Loss) for the period from continuing operations (7-8)	(28.07)	(28.01)	(26.04)	(128.33)
10	Profit/(loss) from discontinuing operations before Tax	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-
13	Profit / (Loss) for the period (9+12)	(28.07)	(28.01)	(26.04)	(128.33)



KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



KAMRON

	Particulars	Quarter ended			Previous Year ended 31-03-2021
		30-06-2021	31-03-2021	30-06-2020	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
14	Other Comprehensive Income	-	-	-	-
	<i>Items that will not be reclassified subsequently to profit or loss</i>				
	Mention Item.....				
	Mention Item.....				
	Mention Item.....				
	Income tax relating to items that will not be reclassified to profit or loss				
	<i>Items that will be reclassified subsequently to profit or loss</i>				
	Mention Item.....				
	Mention Item.....				
	Mention Item.....				
	Income tax relating to items that will be reclassified to profit or loss				
	Other Comprehensive Income, net of tax	-	-	-	-
15	Total Comprehensive Income for the period (13+14)	(28.07)	(28.01)	(26.04)	(128.33)
16	Paid-up equity shares capital (Face Value per share Rs. 10)	585	585	585	585
17	Reserves excluding Revaluation Reserves				
18	Earnings Per Share of Rs.10/- each (for continuing operations)				
	- Basic	(0.48)	(0.48)	(0.44)	(2.19)
	- Diluted	(0.48)	(0.48)	(0.44)	(2.19)
19	Earnings Per Share of Rs.____ each (for discontinued operations)				
	- Basic	-	-	-	-
	- Diluted	-	-	-	-
20	Earnings Per Share of Rs.10/- each (for discontinued & continuing operations)				
	- Basic	(0.48)	(0.48)	(0.44)	(2.19)
	- Diluted	(0.48)	(0.48)	(0.44)	(2.19)



KAMRON LABORATORIES LIMITED

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541
E-mail : info@kamronlabs.com Website: www.kamronlabs.com
CIN : L24231GJ1988PLC010956



KAMRON

Notes:

1	The Company is operating only in one segment i.e. Pharmaceutical products. Hence segment reporting is not given as per last report.
2	The Company has associates with Centis Lifecare pvt ltd. And Kamron Healhtcare pvt. Ltd.
3	Provision for taxation/deferred taxation, if any, will be made at the year end.
4	Figures, wherever required, are regrouped / rearranged.
5	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 14 th August, 2021.
6	The figures for quarter ended 31 st March, 2021 are the balancing figures between the audited figures in respect of the full financial year ended on 31 st March, 2021 and the year to date figures up to the third quarter of the financial year 2020-21.

For KAMRON LABORATORIES LIMITED

Date: 14th August, 2021
Place: Ahmedabad



Kamlesh J. Laskari

KAMLESH J. LASKARI
MANAGING DIRECTOR
(DIN:00461198)

LIMITED REVIEW REPORT**Review report to Board of Directors of Kamron Laboratories Ltd**

We have reviewed the accompanying statement of unaudited standalone financial results of Kamron Laboratories Ltd for the period ended 30th June, 2021, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Rangwala & Co.
Chartered Accountants
(Firm's Registration No. 115833W)


(Z. E. Rangwala)
Partner
(Membership No.031268)
(UDIN: 21031268AAAABL9057)



Date:14/08/2021
Place Ahmedabad